Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Deferred Tax: 2016-2019

  • Niagen Bioscience's Long-Term Deferred Tax rose 38.34% to $30.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $30.5 million, marking a year-over-year increase of 38.34%. This contributed to the annual value of $30.5 million for FY2019, which is 38.34% up from last year.
  • As of Q4 2019, Niagen Bioscience's Long-Term Deferred Tax stood at $30.5 million, which was up 38.34% from $22.1 million recorded in Q4 2018.
  • In the past 5 years, Niagen Bioscience's Long-Term Deferred Tax registered a high of $30.5 million during Q4 2019, and its lowest value of $13.0 million during Q4 2017.
  • For the 3-year period, Niagen Bioscience's Long-Term Deferred Tax averaged around $21.9 million, with its median value being $22.1 million (2018).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first fell by 18.09% in 2017, then spiked by 69.14% in 2018.
  • Over the past 4 years, Niagen Bioscience's Long-Term Deferred Tax (Quarterly) stood at $15.9 million in 2016, then dropped by 18.09% to $13.0 million in 2017, then spiked by 69.14% to $22.1 million in 2018, then skyrocketed by 38.34% to $30.5 million in 2019.
  • Its last three reported values are $30.5 million in Q4 2019, $22.1 million for Q4 2018, and $13.0 million during Q4 2017.